An iPSC-derived vascular model of Marfan syndrome identifies key mediators of smooth muscle cell death

Marfan syndrome (MFS) is a heritable connective tissue disorder caused by mutations in FBN1, which encodes the extracellular matrix protein fibrillin-1. To investigate the pathogenesis of aortic aneurysms in MFS, we generated a vascular model derived from human induced pluripotent stem cells (MFS-hiPSCs). Our MFS-hiPSC-derived smooth muscle cells (SMCs) recapitulated the pathology seen in Marfan aortas, including defects in fibrillin-1 accumulation, extracellular matrix degradation, transforming growth factor-β (TGF-β) signaling, contraction and apoptosis; abnormalities were corrected by CRISPR-based editing of the FBN1 mutation. TGF-β inhibition rescued abnormalities in fibrillin-1 accumulation and matrix metalloproteinase expression. However, only the noncanonical p38 pathway regulated SMC apoptosis, a pathological mechanism also governed by Krüppel-like factor 4 (KLF4). This model has enabled us to dissect the molecular mechanisms of MFS, identify novel targets for treatment (such as p38 and KLF4) and provided an innovative human platform for the testing of new drugs.

[1]  M. Majesky.  Developmental basis of vascular smooth muscle diversity. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[2]  H. Dietz,et al.  p38 MAPK Is an Early Determinant of Promiscuous Smad2/3 Signaling in the Aortas of Fibrillin-1 (Fbn1)-null Mice* , 2009, Journal of Biological Chemistry.

[3]  U. Francke,et al.  Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes. , 1999, American journal of human genetics.

[4]  D. Milewicz,et al.  Treatment of aortic disease in patients with Marfan syndrome. , 2005, Circulation.

[5]  B. Giusti,et al.  FBN1 mutation screening of patients with Marfan syndrome and related disorders: detection of 46 novel FBN1 mutations , 2008, Clinical genetics.

[6]  P. Dijke,et al.  Extracellular control of TGFβ signalling in vascular development and disease , 2007, Nature Reviews Molecular Cell Biology.

[7]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[8]  D. Judge,et al.  Loss of Elastic Fiber Integrity and Reduction of Vascular Smooth Muscle Contraction Resulting From the Upregulated Activities of Matrix Metalloproteinase-2 and -9 in the Thoracic Aortic Aneurysm in Marfan Syndrome , 2007, Circulation research.

[9]  Benjamin S. Brooke,et al.  Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. , 2008, The New England journal of medicine.

[10]  M Claustres,et al.  Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. , 2007, American journal of human genetics.

[11]  H. Dietz,et al.  Marfan syndrome: from molecular pathogenesis to clinical treatment. , 2007, Current opinion in genetics & development.

[12]  D. Arking,et al.  Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. , 2003, Nature genetics.

[13]  J. Pober,et al.  MEK5 is Activated by Shear Stress, Activates ERK5 and Induces KLF4 to Modulate TNF Responses in Human Dermal Microvascular Endothelial Cells , 2011, Microcirculation.

[14]  Samarjit Patnaik,et al.  Noncanonical TGFβ Signaling Contributes to Aortic Aneurysm Progression in Marfan Syndrome Mice , 2011, Science.

[15]  M. Longaker,et al.  Skeletogenic phenotype of human Marfan embryonic stem cells faithfully phenocopied by patient-specific induced-pluripotent stem cells , 2011, Proceedings of the National Academy of Sciences.

[16]  H. Dietz,et al.  Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. Owens,et al.  Molecular regulation of vascular smooth muscle cell differentiation in development and disease. , 2004, Physiological reviews.

[18]  Marie-José Goumans,et al.  TGF-β signaling in vascular biology and dysfunction , 2009, Cell Research.

[19]  M. Trotter,et al.  Derivation of pluripotent epiblast stem cells from mammalian embryos , 2007, Nature.

[20]  E. Schiffrin,et al.  Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. , 2000, Pharmacological reviews.

[21]  M. Trotter,et al.  Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility , 2012, Nature Biotechnology.

[22]  B. Wentworth,et al.  Dimorphic Effects of Transforming Growth Factor-&bgr; Signaling During Aortic Aneurysm Progression in Mice Suggest a Combinatorial Therapy for Marfan Syndrome , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[23]  D. Arking,et al.  Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome , 2003, Nature Genetics.

[24]  Kevin D Costa,et al.  Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. , 2014, The Journal of clinical investigation.

[25]  Qingbo Xu,et al.  Mechanical Stretch-Induced Apoptosis in Smooth Muscle Cells Is Mediated by &bgr;1-Integrin Signaling Pathways , 2003, Hypertension.

[26]  V. Kaartinen,et al.  Fibrillin controls TGF-beta activation. , 2003, Nature genetics.

[27]  Wolfram Kress,et al.  A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 , 2005, Nature Genetics.

[28]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells From Adult Human Fibroblasts by Defined Factors , 2008 .

[29]  C. Béroud,et al.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.

[30]  M. Keane,et al.  Medical management of Marfan syndrome. , 2008, Circulation.

[31]  R. Pedersen,et al.  Directed differentiation of embryonic origin–specific vascular smooth muscle subtypes from human pluripotent stem cells , 2014, Nature Protocols.

[32]  J. Humphrey,et al.  Dysfunctional Mechanosensing in Aneurysms , 2014, Science.

[33]  A. Hughes,et al.  p53, p21(WAF1/CIP1), and MDM2 involvement in the proliferation and apoptosis in an in vitro model of conditionally immortalized human vascular smooth muscle cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[34]  Jeffrey A. Jones,et al.  Transforming Growth Factor-β Signaling in Thoracic Aortic Aneurysm Development: A Paradox in Pathogenesis , 2008, Journal of Vascular Research.

[35]  M. Laiho,et al.  Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. , 1987, The Journal of biological chemistry.

[36]  Ada Hamosh,et al.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene , 1991, Nature.

[37]  J. Stockman,et al.  Noncanonical TGFβ Signaling Contributes to Aortic Aneurysm Progression in Marfan Syndrome Mice , 2012 .

[38]  V. McKusick,et al.  The Marfan syndrome: diagnosis and management. , 1979, The New England journal of medicine.

[39]  H. Dietz,et al.  Targetting of the gene encoding fibrillin–1 recapitulates the vascular aspect of Marfan syndrome , 1997, Nature Genetics.

[40]  J. Michel,et al.  The FASEB Journal express article 10.1096/fj.02-0687fje. Published online May 8, 2003. Pericellular plasmin induces smooth muscle cell anoikis , 2022 .

[41]  P. Handford,et al.  Fibrillin-integrin interactions in health and disease. , 2008, Biochemical Society transactions.

[42]  C. van Breemen,et al.  Dysfunction of endothelial and smooth muscle cells in small arteries of a mouse model of Marfan syndrome , 2009, British journal of pharmacology.

[43]  A. Hughes,et al.  p 53 , p 21 WAF 1 / CIP 1 , and MDM 2 Involvement in the Proliferation and Apoptosis in an In Vitro Model of Conditionally Immortalized Human Vascular Smooth Muscle Cells , 2000 .

[44]  T. Graf.  Faculty Opinions recommendation of Induction of pluripotent stem cells from adult human fibroblasts by defined factors. , 2007 .

[45]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[46]  L. Rénia,et al.  TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. , 2010, The Journal of clinical investigation.

[47]  H. Dietz,et al.  Matrix‐dependent perturbation of TGFβ signaling and disease , 2012, FEBS letters.

[48]  S. Colan,et al.  Atenolol versus losartan in children and young adults with Marfan's syndrome. , 2014, The New England journal of medicine.

[49]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[50]  D. Judge,et al.  Angiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice Through ERK Antagonism , 2011, Science.

[51]  C. Tournier,et al.  Regulation of cellular functions by the ERK5 signalling pathway. , 2006, Cellular signalling.

[52]  R. Pedersen,et al.  Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development , 2010, Hepatology.

[53]  D. Iyer,et al.  Embryonic origins of human vascular smooth muscle cells: implications for in vitro modeling and clinical application , 2014, Cellular and Molecular Life Sciences.

[54]  P. ten Dijke,et al.  Extracellular control of TGFbeta signalling in vascular development and disease. , 2007, Nature reviews. Molecular cell biology.

[55]  K. Berecek,et al.  Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. , 2006, Biochemical and biophysical research communications.

[56]  D. Navajas,et al.  Vascular Smooth Muscle Cell Phenotypic Changes in Patients With Marfan Syndrome , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[57]  P. Robinson,et al.  The molecular genetics of Marfan syndrome and related disorders , 2006, Journal of Medical Genetics.

[58]  Rudolf Winter-Ebmer,et al.  An International Study , 2007 .

[59]  Jay D. Humphrey,et al.  Mechanotransduction and extracellular matrix homeostasis , 2014, Nature Reviews Molecular Cell Biology.

[60]  T. Graham.  Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome , 2009 .

[61]  G. Nickenig,et al.  Induction of p53 by GKLF is essential for inhibition of proliferation of vascular smooth muscle cells. , 2007, Journal of molecular and cellular cardiology.

[62]  Seneca L. Bessling,et al.  Mutations in the TGF-β Repressor SKI Cause Shprintzen-Goldberg Syndrome with Aortic Aneurysm , 2012, Nature Genetics.

[63]  H. Dietz,et al.  Recent progress towards a molecular understanding of Marfan syndrome , 2005, American journal of medical genetics. Part C, Seminars in medical genetics.

[64]  C. van Breemen,et al.  Marfan Syndrome Decreases Ca2+ Wave Frequency and Vasoconstriction in Murine Mesenteric Resistance Arteries without Changing Underlying Mechanisms , 2010, Journal of Vascular Research.

[65]  F. Tubach,et al.  Marfan Sartan: a randomized, double-blind, placebo-controlled trial. , 2015, European heart journal.

[66]  V. Kaartinen,et al.  Fibrillin controls TGF-β activation , 2003, Nature Genetics.

[67]  G. Gibbons,et al.  Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. , 1992, The Journal of clinical investigation.

[68]  Roger A. Pedersen,et al.  Early Cell Fate Decisions of Human Embryonic Stem Cells and Mouse Epiblast Stem Cells Are Controlled by the Same Signalling Pathways , 2009, PloS one.

[69]  V. McKusick,et al.  The Cardiovascular Aspects of Marfan's Syndrome: A Heritable Disorder of Connective Tissue , 1955, Circulation.

[70]  G. Vriend,et al.  Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis , 2011, Nature Genetics.